Roles & Responsibilities:

Multiple postdoctoral positions are immediately available in Shi laboratory of Proteomics, Center for Protein Engineering and Therapeutics at Icahn School of Medicine at Mount Sinai in NYC
The lab is interested in developing biotechnologies for the analysis of biomolecules and macromolecular assemblies, with a focus on mass spectrometry/proteomic techniques. Recently, inspired by the high translational potential of the camelid single-chain antibodies (so called nanobodies), our lab has developed robust pipeline technologies and tools to facilitate nanobody drug discovery and therapeutic applications. The lab is also interested in the development and application of integrative structural approaches to study protein-protein and antibody-protein interactions. An emerging direction of the lab is to conjugate machine learning, structural biology and proteomic approaches to facilitate engineering and design towards novel protein therapeutics and vaccine development. The lab is vibrant, fun, and collaborative and support creative ideas and career development.
References:
Kim, S.J., et al (2018). Integrative structure and functional anatomy of a nuclear pore complex. Nature.
Xiang, Y., et al (2020). Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science.
Nambulli., et al (2021). Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Science Advances.
Xiang, Y., et al (2021). Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies. Cell Systems.
Sun, et al. (2021). Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes. Nature Communications.
Shen et al. (2021). A resource of high-quality nanobodies for drug delivery. iScience.
Sang, et al. (2021) Llamanade: an open-source computational pipeline for robust nanobody humanization. Structure.
Xiang et al (2022). Super-immunity by broadly protective nanobodies to sarbecoviruses. BioRxiv.
The lab is funded by multiple grants including the NIH, AAZ and MJFF. Competitive salaries can be provided for successful candidates.

Visit our lab at: https://www.shi-lab.org/.

Some related news are list here:

• Inhaled nanobodies effective against coronaviurs in hamsters, researchers say (Fox News)
• Llama 'nanobodies’ may yield COVID-19 treatment, Pitt scientists say (The Philadelphia Inquirer)
• Why the lovable llama might be a secret weapon against COVID-19 (Argonne National Library)
• https://pittnews.com/article/161919/top-stories/pitt-researchers-find-covid-19-breakthrough-in-llama-nanobodies/
• https://www.upmc.com/media/news/052621-shi-duprex-pin21
• https://www.innovation.pitt.edu/2020/11/antennabiotech/
• https://www.upmc.com/media/news/021521-shi-massspecproteomics
• Nasal spray gives Pitt researchers a promising new weapon to fight COVID (Next Pittsburgh)
• Pitt Researchers Discover Llama ‘Nanobodies’ Are Powerful New Coronavirus Treatment (CBS Local)
• Pitt team discovers new way to find nanbodies to fight disease (WPXI)
• Pitt scientists unveil potential 'powerful' treatment for COVID-19 using llama nanobodies (WJAC)
• Pitt researchers say llamas may help research and treatment of COVID (WTAE)
• Alpacas and llamas may hold the key to alternative COVID-19 vaccine (Fox 8)
• Llama antibodies? Why researchers say they could be powerful weapon against COVID-19 (ABC 7)
• Researchers hope to harness power of llama nanobodies to treat coronavirus (Fox 43)
• Inhaled antibody fragments protect infected animals against COVID-19 (The Scientist)
• Inhalable nanobody shows potent anti-SARS-CoV2 activity in vivo (Medical.net)
• Scientists Cure COVID in Hamsters With Inhaled Nanobodies: Study (Gadgets 360)
• Llama nanobodes are a powerful bew COVID-19 treatment: Study (The New York Post)
• Asthma style inhalter of tiny nanobodies cleared COVID infection in hamsters (Daily Mail UK)
• Inhaled COVID Meds and 'Simple, Self-Administered' Care (Medscape)
• Neutralizing nanobodies effective against SARS-CoV2 variants (Medical.net)

Requirements:

Motivated individuals (PhD or MD) with a background in mass spectrometry-based proteomics, microbiology, structural biology (such as cryo-EM), and cancer immunology (ideally with animal model experience) are particularly welcome to apply. Interested candidates may submit their CV, including names and contact information for two-three references, a short description of their research experience, and goals to Yi Shi at (yi.shi@mssm.edu).

Responsibilities

.

Qualifications

.

Strength through Unity and Inclusion

The Mount Sinai Health System is committed to fostering an environment where everyone can contribute to excellence. We share a common dedication to delivering outstanding patient care. When you join us, you become part of Mount Sinai’s unparalleled legacy of achievement, education, and innovation as we work together to transform healthcare. We encourage all team members to actively participate in creating a culture that ensures fair access to opportunities, promotes inclusive practices, and supports the success of every individual.

At Mount Sinai, our leaders are committed to fostering a workplace where all employees feel valued, respected, and empowered to grow. We strive to create an environment where collaboration, fairness, and continuous learning drive positive change, improving the well-being of our staff, patients, and organization. Our leaders are expected to challenge outdated practices, promote a culture of respect, and work toward meaningful improvements that enhance patient care and workplace experiences. We are dedicated to building a supportive and welcoming environment where everyone has the opportunity to thrive and advance professionally. Explore this opportunity and be part of the next chapter in our history.

About the Mount Sinai Health System:

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes more than 9,000 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics, top 5 in Cardiology/Heart Surgery, and top 20 in Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is ranked No. 11 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

Equal Opportunity Employer

The Mount Sinai Health System is an equal opportunity employer, complying with all applicable federal civil rights laws. We do not discriminate, exclude, or treat individuals differently based on race, color, national origin, age, religion, disability, sex, sexual orientation, gender, veteran status, or any other characteristic protected by law. We are deeply committed to fostering an environment where all faculty, staff, students, trainees, patients, visitors, and the communities we serve feel respected and supported. Our goal is to create a healthcare and learning institution that actively works to remove barriers, address challenges, and promote fairness in all aspects of our organization.